Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about BRVE, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| BHB-1893 | Cardiomyopathy, Hypertrophic Obstructive | Phase 3 · NCT07755904 | Recruiting |
Also used in these trials (approved or third-party drugs, not BRVE's own candidates): Metoprolol.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
BRVE holds $503.5M in cash and short-term investments (as of Sep 30, 2026) and burns about $12.6M/quarter from operations, an estimated runway of 120.3 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 0 · Low
Based on our current operating plan, we believe that our existing cash, cash equivalents and investments will be sufficient to fund our projected operating expenses and capital expenditure requirements into 2029.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when BRVE files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC Director, 10% owner |
Insider | 12,175,159 | 13.55% | 2026-09-08 |
| Forbion Growth Opportunities Fund III Co 10% owner |
Insider | 11,640,546 | 12.95% | 2026-09-30 |
| Vineeta Agarwala Director |
Insider | 10,232,420 | 11.39% | 2026-08-07 |
| AH Bio Fund IV, L.P. 10% owner Includes shares also reported by Vineeta Agarwala, counted once |
Insider | 10,232,420 | 11.39% | 2026-08-07 |
| Travis Murdoch CEO and President, Director · +550,000 options |
Insider | 8,379,470 | 9.32% | 2026-09-30 |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd 10% owner |
Insider | 7,420,091 | 8.26% | 2026-09-30 |
| FMR LLC | Institution (13G, 5%+) | 7,374,365 | 8.21% | 2026-09-30 |
| Frazier Life Sciences Public Fund, L.P. | 5%+ holder (13G) | 4,976,457 | 5.54% | 2026-08-07 |
| Jason V Coloma Director |
Insider | 1,100,456 | 1.22% | 2026-08-05 |
| David I Malek Director · +30,000 options |
Insider | 1,013,297 | 1.13% | 2026-08-05 |
| Christopher Viehbacher Director · +30,000 options |
Insider | 759,857 | 0.85% | 2026-08-05 |
| James Paul Rickey Chief Financial Officer · +300,000 options |
Insider | 703,575 | 0.78% | 2026-08-05 |
Share count 89,870,352 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BRVE and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →